Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that […]